LKT Laboratories, Inc.

RAF265

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID R0020

CAS No. 927880-90-8

Chemical Name 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine

Synonym



Formula $C_{24}H_{16}F_6N_6O$

Formula Wt. 518.4

Melting Point

Purity ≥98%

Solubility

DMSO	100 mg/mL (192.89 mM)
Ethanol	33 mg/mL (63.65 mM)
Water	Insoluble

Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
R0020	1 mg	$119.10
R0020	5 mg	$357.30

Store Temp -20˚C

Ship Temp Ambient

Description RAF265 is an orally bioavailable anticancer chemotherapeutic compound that inhibits primarily WT B-Raf, mutant (V600E) B-Raf, and VEGFR2, but is also active against c-Raf, PDGFR, CSF-1R, RET, c-Kit, Src, and STE20. This compound is in clinical trials as a treatment for unresectable or metastatic melanoma. Inhibition of B-Raf by RAF265 attenuates downstream ERK and RET signaling, preventing tumor cell proliferation. Raf265-induced alterations in ERK signaling also decreases expression of c-fos and NFATc1, inhibiting in vitro differentiation of PBMCs to osteoclasts and inhibiting osteoclast resorptive capacity, therefore inhibiting osteoclastogenesis.

References

Garcia-Gomez A, Ocio EM, Pandiella A, et al. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5. d PMID: 22773056.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Su Y, Vilgelm AE, Kelley MC, et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res. 2012 Apr 15;18(8):2184-98. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475. PMID: 22351689.